Tariff-related Litigation Update – 6/27
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.
My Profile
Member Center
Policy
Top Priorities
On behalf of our members, AdvaMed® works on countless fronts to ensure patients have timely access to life-changing technologies. Find out more about our top policy issues.
Your Featured Resources
Tariff-related Litigation Update – 6/20
Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.
Tariff-related Litigation Update
Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.
Week 6: Regulatory Shifts, Tariff Action & Industry Feedback
USTR proposes new China tariffs; FDA, CMS, and White House actions could reshape MedTech—member input needed by June 10.
AdvaMed Response to House Privacy Working Group RFI
AdvaMed calls for federal privacy laws that reflect how medical devices use patient data differently from consumer health tools.
AdvaMed Comments to DOJ Anticompetitive Regulations RFC
AdvaMed urges DOJ to remove outdated rules that block medtech innovation and limit access to lifesaving technology.
Additional Resources
Tariff-related Litigation Update – 6/27
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.
Tariff-related Litigation Update – 6/20
Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.
Tariff-related Litigation Update
Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.
Week 6: Regulatory Shifts, Tariff Action & Industry Feedback
USTR proposes new China tariffs; FDA, CMS, and White House actions could reshape MedTech—member input needed by June 10.
Discover More Resources
AdvaMed® members have access to our full library of industry resources.
You are not logged in to the AdvaMed Hub.
Celebrating 50 Years of MedTech Innovation: Why You Can’t Miss #MTC25
Join thousands of industry leaders October 5-8, 2025, in San Diego, California for direct access to hundreds of hours of timely medtech education, networking with industry leaders and CEOs, and…
Medtech Goes to Capitol Hill
AdvaMed’s annual Medtech Showcase and Reception on Capitol Hill seeks to inform a core audience: the members of the Congress and their staff who enact the policies that help our…
Cardiawave Announces Positive 12-Month Results from Its “Valvosoft® FIM Study” and “Valvosoft® Pivotal Study” for the Treatment of Severe Symptomatic Aortic Stenosis (sSAS)
Levallois-Perret, France – May 22, 2025 — Cardiawave SA, medtech company specialized in valvular heart disease, presented today at the EuroPCR Congress the 12-month results from its “Valvosoft® FIM Study”…
Medtech is Essential: Industry Supports Call for Tariff Flexibility
AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly,…
AdvaMed Welcomes Introduction of American Innovation and Jobs Act
WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen…
AdvaMed Welcomes Introduction of Access to Prescription Digital Therapeutics Act
WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen…
AdvaMed Welcomes the Re-Introduction of the Ensuring Patient Access to Critical Breakthrough Products Act
Washington, D.C.–AdvaMed President and CEO Scott Whitaker released the following statement upon re-introduction of bipartisan legislation aimed at accelerating Medicare coverage for breakthrough medtech and diagnostics. The Ensuring Patient Access…
Orthogonal, Kwame Ulmer on the Value of AdvaMed Membership
At AdvaMed, we’re proud to be recognized for our work on behalf of the medtech community – and we’re especially grateful when that recognition comes from respected voices like Kwame…
Swiss Medtech and AdvaMed Call for Zero for Zero Tariffs and Recognition of FDA Approvals and Clearances
Bern/Washington – Swiss Medtech, the leading trade association for medical technology companies in Switzerland, and AdvaMed, the U.S. Medtech Association and the world’s largest organization representing medtech innovators, are jointly…
AdvaMed Testifies in U.S. Senate
WASHINGTON – Today, President and CEO Scott Whitaker of AdvaMed, the Medtech Association, testified before the U.S. Senate Committee on Finance in its hearing focused on the impact of tariffs…
Membership Newsletter
We are pleased to provide AdvaMed® members with the Membership Newsletter, a monthly publication designed to communicate relevant news, resources, events and policy updates.